Cargando…
Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
Chemotherapy-induced nausea and vomiting (CINV) negatively impact cancer patients’ quality of life and treatment outcomes. This study evaluated the achievement of complete response to CINV prophylaxis during the first five days after chemotherapy in adult outpatient cancer clinics with solid maligna...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954894/ https://www.ncbi.nlm.nih.gov/pubmed/36826078 http://dx.doi.org/10.3390/curroncol30020117 |
_version_ | 1784894225750425600 |
---|---|
author | Araújo, António Tavares, Nuno Faria, Ana Luísa Gomes, Rosa Mendonça, Joana Carvalho Parente, Bárbara Capela, Andreia Barata, Fernando Macedo, Ana |
author_facet | Araújo, António Tavares, Nuno Faria, Ana Luísa Gomes, Rosa Mendonça, Joana Carvalho Parente, Bárbara Capela, Andreia Barata, Fernando Macedo, Ana |
author_sort | Araújo, António |
collection | PubMed |
description | Chemotherapy-induced nausea and vomiting (CINV) negatively impact cancer patients’ quality of life and treatment outcomes. This study evaluated the achievement of complete response to CINV prophylaxis during the first five days after chemotherapy in adult outpatient cancer clinics with solid malignant tumours receiving Moderate or Highly Emetogenic Chemotherapy (MEC or HEC) in Portugal. During the study, patients completed three evaluations, and nausea severity and CINV impact on patients’ daily life was assessed. A complete response (no emetic episodes, no use of rescue antiemetic medication, and no more than mild nausea) was observed in 72% of the cycles (N = 161) throughout the five days after chemotherapy. Amongst the patient population, 25% classified their CINV episodes as severe. Though more than half of the patients achieved a complete response, suggesting that a therapeutic effort is being made to minimise this side effect, the overall scenario is barely optimistic. Significantly, new CINV-control measures in MEC/HEC patients should be adopted, specifically avoiding the single use of dexamethasone and 5-HT3 and raising awareness of using NK1-RAs. Thus, it is critical to improve CINV prophylactic treatment and implement practical international antiemetic guidelines in Portuguese clinical practice, envisaging the improvement of supportive care for cancer patients. |
format | Online Article Text |
id | pubmed-9954894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99548942023-02-25 Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal Araújo, António Tavares, Nuno Faria, Ana Luísa Gomes, Rosa Mendonça, Joana Carvalho Parente, Bárbara Capela, Andreia Barata, Fernando Macedo, Ana Curr Oncol Article Chemotherapy-induced nausea and vomiting (CINV) negatively impact cancer patients’ quality of life and treatment outcomes. This study evaluated the achievement of complete response to CINV prophylaxis during the first five days after chemotherapy in adult outpatient cancer clinics with solid malignant tumours receiving Moderate or Highly Emetogenic Chemotherapy (MEC or HEC) in Portugal. During the study, patients completed three evaluations, and nausea severity and CINV impact on patients’ daily life was assessed. A complete response (no emetic episodes, no use of rescue antiemetic medication, and no more than mild nausea) was observed in 72% of the cycles (N = 161) throughout the five days after chemotherapy. Amongst the patient population, 25% classified their CINV episodes as severe. Though more than half of the patients achieved a complete response, suggesting that a therapeutic effort is being made to minimise this side effect, the overall scenario is barely optimistic. Significantly, new CINV-control measures in MEC/HEC patients should be adopted, specifically avoiding the single use of dexamethasone and 5-HT3 and raising awareness of using NK1-RAs. Thus, it is critical to improve CINV prophylactic treatment and implement practical international antiemetic guidelines in Portuguese clinical practice, envisaging the improvement of supportive care for cancer patients. MDPI 2023-01-24 /pmc/articles/PMC9954894/ /pubmed/36826078 http://dx.doi.org/10.3390/curroncol30020117 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Araújo, António Tavares, Nuno Faria, Ana Luísa Gomes, Rosa Mendonça, Joana Carvalho Parente, Bárbara Capela, Andreia Barata, Fernando Macedo, Ana Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal |
title | Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal |
title_full | Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal |
title_fullStr | Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal |
title_full_unstemmed | Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal |
title_short | Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal |
title_sort | evaluation of current antiemetic therapy response in patients undergoing mec or hec regimens in portugal |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954894/ https://www.ncbi.nlm.nih.gov/pubmed/36826078 http://dx.doi.org/10.3390/curroncol30020117 |
work_keys_str_mv | AT araujoantonio evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal AT tavaresnuno evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal AT fariaanaluisa evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal AT gomesrosa evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal AT mendoncajoanacarvalho evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal AT parentebarbara evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal AT capelaandreia evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal AT baratafernando evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal AT macedoana evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal |